Primmune Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $23.3M

  • Investors
  • 9

Primmune Therapeutics General Information

Description

Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. The company's agonist produces cytokines and chemokines that up-regulate general cellular response and facilitate natural killer cell activation, enabling medical practitioners to address all metastatic diseases and stimulate B-cell proliferation and activation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • JLABS San Diego
  • 3210 Merryfield Row
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • JLABS San Diego
  • 3210 Merryfield Row
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Primmune Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 26-Jan-2026 $23.3M Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) 12-Jan-2021 Completed Clinical Trials - Phase 1
3. Seed Round 02-Mar-2020 Completed Clinical Trials - Phase 1
2. Seed Round 29-Jan-2018 $1.52M $1.52M Completed Startup
1. Accelerator/Incubator 03-Jan-2018 Completed Startup
To view Primmune Therapeutics’s complete valuation and funding history, request access »

Primmune Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series AA2
Series AA1 1,964,696 $0.000100 $0.78 $0.78 1x $0.78 7.97%
To view Primmune Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Primmune Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunothe
Drug Discovery
San Diego, CA
10 As of 2025

Santa Monica, CA
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Primmune Therapeutics Competitors (67)

One of Primmune Therapeutics’s 67 competitors is Kite Pharma, a Formerly VC-backed company based in Santa Monica, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Senti Biosciences Holdings Formerly VC-backed South San Francisco, CA
Instil Bio Formerly VC-backed Dallas, TX
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 67 competitors. Get the full list »

Primmune Therapeutics Patents

Primmune Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220324800-A1 Sars-3cl protease inhibitors Inactive 01-Apr-2021
WO-2022212707-A1 Sars-3cl protease inhibitors Inactive 01-Apr-2021
JP-2023503996-A Tlr7 agonist Active 26-Nov-2019
JP-7777870-B2 Tlr7 agonist Active 26-Nov-2019
AU-2020391487-A1 Tlr7 agonists Active 26-Nov-2019 C07H19/16
To view Primmune Therapeutics’s complete patent history, request access »

Primmune Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Primmune Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bioqube Ventures Venture Capital Minority
Oberland Capital PE/Buyout Minority
Polaris Partners Venture Capital Minority
Samsara BioCapital Venture Capital Minority
Biobrit Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Primmune Therapeutics FAQs

  • When was Primmune Therapeutics founded?

    Primmune Therapeutics was founded in 2017.

  • Where is Primmune Therapeutics headquartered?

    Primmune Therapeutics is headquartered in San Diego, CA.

  • What is the size of Primmune Therapeutics?

    Primmune Therapeutics has 10 total employees.

  • What industry is Primmune Therapeutics in?

    Primmune Therapeutics’s primary industry is Drug Discovery.

  • Is Primmune Therapeutics a private or public company?

    Primmune Therapeutics is a Private company.

  • What is Primmune Therapeutics’s current revenue?

    The current revenue for Primmune Therapeutics is .

  • How much funding has Primmune Therapeutics raised over time?

    Primmune Therapeutics has raised $63.2M.

  • Who are Primmune Therapeutics’s investors?

    Bioqube Ventures, Oberland Capital, Polaris Partners, Samsara BioCapital, and Biobrit are 5 of 9 investors who have invested in Primmune Therapeutics.

  • Who are Primmune Therapeutics’s competitors?

    Kite Pharma, Carisma Therapeutics, Senti Biosciences Holdings, Instil Bio, and Inovio Pharmaceuticals are some of the 67 competitors of Primmune Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process